ArticleJournal of cardiothoracic surgery2026
Association between the TP63 and CIR1 polymorphisms and non-small cell lung cancer in Chinese population.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesLung cancer is a leading cause of cancer-related death globally, with non-small cell lung cancer (NSCLC) being the predominant form. Genetic factors significantly influence individual susceptibility. This study investigated the association of TP63 (rs7631358) and CIR1 (rs13009079) polymorphisms with NSCLC risk in a Chinese population.
methodsA case-control study was conducted with 500 NSCLC patients and 500 matched controls. Genotyping was performed using the SEQUENOM MassARRAY platform. Associations were evaluated using chi-square tests and logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs).
resultsIn the pre-specified primary analysis with FDR correction, both TP63 rs7631358 (A/G + A/A vs. G/G: adjusted OR = 1.409, FDR P = 0.030) and CIR1 rs13009079 (T/T vs. C/T + C/C: adjusted OR = 1.390, FDR P = 0.030) were significantly associated with an increased risk of lung adenocarcinoma after adjustment for smoking status, gender, and age. Exploratory subgroup analyses suggested that the TP63 association was more pronounced among ever-smokers, although the gene-smoking interaction did not reach statistical significance.
conclusionsTP63 rs7631358 and CIR1 rs13009079 polymorphisms are significantly associated with the susceptibility to lung adenocarcinoma in the Chinese Han population after correction for multiple testing. These findings support a role for the TP63-mediated DNA damage response pathway and the CIR1-Notch signaling pathway in ADC pathogenesis. Replication in larger, independent cohorts is warranted to confirm these associations and to further evaluate their potential for clinical risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.